查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1807689

痛风治疗药的全球市场:市场规模·占有率·趋势，产业分析 (病情·各类药物·各流通管道·各地区)，2025～2034年的市场预测

Gout Therapeutics Market Size, Share, Trend, Industry Analysis Report By Disease Condition (Acute Gout, Chronic Gout), By Drug Class, By Distribution Channel, By Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 128 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，痛风药物市场预计到 2034 年将达到 61.5 亿美元。本研究报告深入分析了当前的市场动态，并分析了未来的市场成长。

痛风药物市场满足了临床对高尿酸血症和单钠尿酸盐晶体沉积引起的复发性发炎性关节炎的治疗需求。治疗包括急性期治疗和长期降尿酸策略，以防止疾病发作和关节损伤。市场成长的驱动因素包括肥胖率上升、久坐不动的生活方式以及高血压和慢性肾臟病等代谢性疾病负担的增加。快速诊断和患者及医疗保健提供者认知度的提高，使得治疗能够更早开始，从而扩大了符合治疗干预条件的患者群体。

业内公司正在投资标靶疗法，以提高疗效，同时最大限度地减少不良事件，尤其是针对对常规治疗无效的患者。生物製剂创新、精准医疗方法以及对合併症敏感型製剂的关注等趋势正日益受到关注。尿酸转运调节剂和白血球介素-1B抑制剂的研发管线不断扩大，正在创造新的商机。监管机构正在为突破性疗法提供快速开发途径，鼓励研发投资。各公司正在结成策略联盟，共同开发和商业化新药，利用共享的专业知识和区域市场准入。市场也正在向以患者为中心的医疗模式转变，该模式融合了治疗依从性工具和数位健康整合。

痛风治疗市场：分析概述

按药物类别划分，非类固醇抗发炎药 (NSAID) 将占市场主导地位，到 2024 年将占总销售额的约 43%，因为它能够快速抑制急性痛风发作相关的发炎和疼痛。

按疾病类型划分，由于对长期管理疗法的需求不断增长，因此慢性痛风预计将在2024年占最大的销售占有率。

2024年，北美占了痛风治疗市场的50%，这得益于其强大的医疗基础设施、早期诊断以及广泛普及的专业风湿病治疗。

预计亚太市场将在2025年至2034年期间实现最高的复合年增长率，这得益于人们对痛风治疗的认识不断提高、医疗保健可及性的改善以及导致高尿酸血症的生活方式相关疾病的患病率不断上升。

主要的全球公司包括Arrowhead Pharmaceuticals, Inc.、阿斯特捷利康、葛兰素史克公司、卫材株式会社、默克公司、诺华公司、再生元製药公司、武田药品工业株式会社、帝人製药有限公司和Zydus集团。

目录

第1章 简介

第2章 摘要整理

第3章 分析方法

第4章 全球痛风治疗药市场洞察

  • 市场概况
  • 痛风治疗市场动态
    • 驱动因素与机遇
      • 痛风及生活型态相关疾病盛行率上升
      • 老年人口基数扩大
    • 限制与课题
      • 新兴市场先进疗法的高成本和报销限制
  • PESTLE分析
  • 痛风治疗市场趋势
  • 价值链分析

第5章 全球痛风治疗药市场:各类药物

  • 主要的分析结果
  • 简介
  • NSAID
  • 皮质类固醇
  • 秋水仙碱
  • 尿酸价值低泻药
  • 其他

第6章 全球痛风治疗药市场:病情

  • 主要的分析结果
  • 简介
  • 急性痛风
  • 慢性痛风

第7章 全球痛风治疗药市场:各流通管道

  • 主要的分析结果
  • 简介
  • 医院药局
  • 零售药局
  • 线上药局

第8章 全球痛风治疗药市场:各地区

  • 主要的分析结果
  • 简介
    • 痛风治疗药市场分析:各地区 (2020～2034年)
  • 北美
    • 北美:各类药物(2020～2034年)
    • 北美:各病情(2020～2034年)
    • 北美:各流通管道(2020～2034年)
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲:各类药物(2020～2034年)
    • 欧洲:各病情(2020～2034年)
    • 欧洲:各流通管道(2020～2034年)
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 亚太地区:各类药物(2020～2034年)
    • 亚太地区:各病情(2020～2034年)
    • 亚太地区:各流通管道(2020～2034年)
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东·非洲
    • 中东·非洲:各类药物(2020～2034年)
    • 中东·非洲:各病情(2020～2034年)
    • 中东·非洲:各流通管道(2020～2034年)
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东·非洲
  • 南美
    • 南美:各类药物(2020～2034年)
    • 南美:各病情(2020～2034年)
    • 南美:各流通管道(2020～2034年)
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美国家

第9章 竞争情形

  • 事业扩大·企业收购的分析
    • 事业扩大
    • 企业收购
  • 联盟/合作/协定/公开

第10章 企业简介

  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca
  • Eisai Co., Ltd.
  • GSK plc.
  • Merck & Co., Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Ltd.
  • Zydus Group
  • Regeneron Pharmaceuticals Inc.
Product Code: PM1611

The gout therapeutics market size is expected to reach USD 6.15 billion by 2034, according to a new study by Polaris Market Research. The report "Gout Therapeutics Market Size, Share, Trend, Industry Analysis Report By Disease Condition (Acute Gout, Chronic Gout), By Drug Class, By Distribution Channel, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The gout therapeutics market addresses the clinical need for managing hyperuricemia and recurrent inflammatory arthritis resulting from monosodium urate crystal deposition. Treatment involves both acute management and long-term urate-lowering strategies to prevent flares and joint damage. Market growth is being driven by increasing disease burden, driven in part by rising obesity rates, sedentary lifestyles, and associated metabolic conditions such as hypertension and chronic kidney disease. Accelerated diagnostic timelines and increased awareness among both patients and healthcare providers are leading to earlier treatment initiation, expanding the patient pool for therapeutic intervention.

Industry players are investing in targeted therapies that minimize adverse events while offering improved efficacy, particularly for patients unresponsive to conventional treatment. Trends such as biologic innovation, precision medicine approaches, and focus on comorbidity-friendly formulations are gaining traction. Opportunities are emerging through pipeline expansion in urate transport modulation and interleukin-1B inhibition. Regulatory bodies are providing fast-track pathways for breakthrough therapies, encouraging R&D investments. Companies are forming strategic collaborations to co-develop and commercialize novel agents, leveraging shared expertise and regional market access. The market is also witnessing a shift toward patient-centric care models, incorporating treatment adherence tools and digital health integration.

Gout Therapeutics Market Report Highlights

By drug class, the NSAIDs segment dominated the market with ~43% of the revenue share in 2024 due to their rapid action in reducing inflammation and pain associated with acute gout flares.

Based on disease condition, the chronic gout segment held the largest revenue share in 2024 due to growing demand for long-term management therapies.

North America accounted for ~50% of the gout therapeutics market revenue share in 2024 due to strong healthcare infrastructure, early diagnosis, and widespread access to specialized rheumatology care.

The market in Asia Pacific is expected to register the highest CAGR from 2025 to 2034 due to growing awareness about gout treatment, improving healthcare access, and the rising prevalence of lifestyle diseases contributing to hyperuricemia.

A few global key players include Arrowhead Pharmaceuticals, Inc.; AstraZeneca; GSK plc.; Eisai Co., Ltd.; Merck & Co., Inc.; Novartis AG; Regeneron Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; Teijin Pharma Ltd.; and Zydus Group.

Polaris Market Research has segmented the market report on the basis of disease condition, drug class, distribution channel, and region:

By Disease Condition Outlook (Revenue, USD Billion, 2020-2034)

Acute Gout

Chronic Gout

By Drug Class Outlook (Revenue, USD Billion, 2020-2034)

NSAIDs

Corticosteroids

Colchicine

Urate-Lowering Agents

Others

By Distribution Channel Outlook (Revenue, USD Billion, 2020-2034)

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Gout Therapeutics Market Insights

  • 4.1. Gout Therapeutics Market - Market Snapshot
  • 4.2. Gout Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Prevalence of Gout and Lifestyle Disorders
      • 4.2.1.2. Increased Geriatric Population Base
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of advanced therapies and limited reimbursement in emerging markets.
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Gout Therapeutics Market Trends
  • 4.6. Value Chain Analysis

5. Global Gout Therapeutics Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • 5.3. NSAIDs
    • 5.3.1. Global Gout Therapeutics Market, by NSAIDs, by Region, 2020-2034 (USD Billion)
  • 5.4. Corticosteroids
    • 5.4.1. Global Gout Therapeutics Market, by Corticosteroids, by Region, 2020-2034 (USD Billion)
  • 5.5. Colchicine
    • 5.5.1. Global Gout Therapeutics Market, by Colchicine, by Region, 2020-2034 (USD Billion)
  • 5.6. Urate-Lowering Agents
    • 5.6.1. Global Gout Therapeutics Market, by Urate-Lowering Agents, by Region, 2020-2034 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Gout Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Gout Therapeutics Market, by Disease Condition

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • 6.3. Acute Gout
    • 6.3.1. Global Gout Therapeutics Market, by Acute Gout, by Region, 2020-2034 (USD Billion)
  • 6.4. Chronic Gout
    • 6.4.1. Global Gout Therapeutics Market, by Chronic Gout, by Region, 2020-2034 (USD Billion)

7. Global Gout Therapeutics Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.3. Hospital Pharmacy
    • 7.3.1. Global Gout Therapeutics Market, by Hospital Pharmacy, by Region, 2020-2034 (USD Billion)
  • 7.4. Retail Pharmacy
    • 7.4.1. Global Gout Therapeutics Market, by Retail Pharmacy, by Region, 2020-2034 (USD Billion)
  • 7.5. Online Pharmacy
    • 7.5.1. Global Gout Therapeutics Market, by Online Pharmacy, by Region, 2020-2034 (USD Billion)

8. Global Gout Therapeutics Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Gout Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Gout Therapeutics Market - North America
    • 8.3.1. North America: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
    • 8.3.2. North America: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
    • 8.3.3. North America: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.4. Gout Therapeutics Market - U.S.
      • 8.3.4.1. U.S.: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.3.4.2. U.S.: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.3.4.3. U.S.: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.5. Gout Therapeutics Market - Canada
      • 8.3.5.1. Canada: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4. Gout Therapeutics Market - Europe
    • 8.4.1. Europe: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.4. Gout Therapeutics Market - UK
      • 8.4.4.1. UK: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.5. Gout Therapeutics Market - France
      • 8.4.5.1. France: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.6. Gout Therapeutics Market - Germany
      • 8.4.6.1. Germany: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.7. Gout Therapeutics Market - Italy
      • 8.4.7.1. Italy: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.8. Gout Therapeutics Market - Spain
      • 8.4.8.1. Spain: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.9. Gout Therapeutics Market - Netherlands
      • 8.4.9.1. Netherlands: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.10. Gout Therapeutics Market - Russia
      • 8.4.10.1. Russia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.11. Gout Therapeutics Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5. Gout Therapeutics Market - Asia Pacific
    • 8.5.1. Asia Pacific: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.4. Gout Therapeutics Market - China
      • 8.5.4.1. China: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.5. Gout Therapeutics Market - India
      • 8.5.5.1. India: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.6. Gout Therapeutics Market - Malaysia
      • 8.5.6.1. Malaysia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.7. Gout Therapeutics Market - Japan
      • 8.5.7.1. Japan: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.8. Gout Therapeutics Market - Indonesia
      • 8.5.8.1. Indonesia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.9. Gout Therapeutics Market - South Korea
      • 8.5.9.1. South Korea: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.10. Gout Therapeutics Market - Australia
      • 8.5.10.1. Australia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.11. Gout Therapeutics Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6. Gout Therapeutics Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.4. Gout Therapeutics Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.5. Gout Therapeutics Market - UAE
      • 8.6.5.1. UAE: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.6. Gout Therapeutics Market - Israel
      • 8.6.6.1. Israel: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.7. Gout Therapeutics Market - South Africa
      • 8.6.7.1. South Africa: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.8. Gout Therapeutics Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7. Gout Therapeutics Market - Latin America
    • 8.7.1. Latin America: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.4. Gout Therapeutics Market - Mexico
      • 8.7.4.1. Mexico: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.5. Gout Therapeutics Market - Brazil
      • 8.7.5.1. Brazil: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.6. Gout Therapeutics Market - Argentina
      • 8.7.6.1. Argentina: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.7. Gout Therapeutics Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Arrowhead Pharmaceuticals, Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AstraZeneca
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Eisai Co., Ltd.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. GSK plc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Merck & Co., Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Novartis AG
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Takeda Pharmaceutical Company Limited
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Teijin Pharma Ltd.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Zydus Group
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Regeneron Pharmaceuticals Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables:

  • Table 1 Global Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 2 Global Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 3 Global Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 4 North America: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 5 North America: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 6 North America: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 7 U.S.: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 8 U.S.: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 9 U.S.: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 10 Canada: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 11 Canada: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 12 Canada: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 13 Europe: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 14 Europe: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 15 Europe: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 16 UK: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 17 UK: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 18 UK: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 19 France: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 20 France: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 21 France: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 22 Germany: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 23 Germany: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 24 Germany: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 25 Italy: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 26 Italy: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 27 Italy: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 28 Spain: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 29 Spain: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 30 Spain: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 31 Netherlands: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 32 Netherlands: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 33 Netherlands: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 34 Russia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 35 Russia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 36 Russia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 37 Rest of Europe: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 38 Rest of Europe: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 39 Rest of Europe: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 40 Asia Pacific: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 41 Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 42 Asia Pacific: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 43 China: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 44 China: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 45 China: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 46 India: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 47 India: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 48 India: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 49 Malaysia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 50 Malaysia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 51 Malaysia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 52 Japan: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 53 Japan: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 54 Japan: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 55 Indonesia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 56 Indonesia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 57 Indonesia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 58 South Korea: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 59 South Korea: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 60 South Korea: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 61 Australia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 62 Australia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 63 Australia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 64 Rest of Asia Pacific: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 65 Rest of Asia Pacific: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 66 Rest of Asia Pacific: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 67 Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 68 Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 69 Middle East & Africa: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 70 Saudi Arabia: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 71 Saudi Arabia: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 72 Saudi Arabia: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 73 UAE: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 74 UAE: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 75 UAE: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 76 Israel: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 77 Israel: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 78 Israel: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 79 South Africa: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 80 South Africa: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 81 South Africa: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 82 Rest of Middle East & Africa: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 83 Rest of Middle East & Africa: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 84 Rest of Middle East & Africa: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 85 Latin America: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 86 Latin America: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 87 Latin America: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 88 Mexico: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 89 Mexico: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 90 Mexico: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 91 Brazil: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 92 Brazil: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 93 Brazil: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 94 Argentina: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 95 Argentina: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 96 Argentina: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 97 Rest of Latin America: Gout Therapeutics Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 98 Rest of Latin America: Gout Therapeutics Market, by Disease Condition, 2020-2034 (USD Billion)
  • Table 99 Rest of Latin America: Gout Therapeutics Market, by Distribution Channel, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Gout Therapeutics Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Class
  • Figure 7. Global Gout Therapeutics Market, by Drug Class, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Disease Condition
  • Figure 9. Global Gout Therapeutics Market, by Disease Condition, 2024 & 2034 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Gout Therapeutics Market, by Distribution Channel, 2024 & 2034 (USD Billion)